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AF	between	 January	2007	and	 January	2016.	Of	 these,	 29	events	 in	27	patients	
(1.18%:	22	men;	64.5	±	10.4	years;	 17	with	paroxysmal	AF)	 of	 cardiac	 tamponade	
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1  | INTRODUC TION
The	effectiveness	of	catheter	ablation	therapy	for	atrial	fibrilla-









cardiac	 tamponade	was	 the	most	 frequent	 cause	of	procedure-	
related death.3,4	The	incidence	rate	of	cardiac	tamponade	is	ap-
proximately	1%-	1.31%	but	subsequent	patient	outcomes	are	not	
clear.1,2,5	 Further,	 the	 use	 of	 direct	 oral	 anticoagulants	 (DOAC)	
has	 recently	 increased	 all	 over	 the	world.6	 The	 association	 be-
tween	this	change	in	anticoagulant	therapy	and	cardiac	tampon-
ade	 is	 still	 unclear.	 In	addition,	 although	pericarditis	 sometimes	
occurs	 alongside	 cardiac	 tamponade,	 the	 relationship	 between	
them	 remains	 poorly	 understood.	 Distinctive	 cases	 of	 delayed	
cardiac	tamponade	after	AF	ablation	have	also	been	reported,7-9 
TABLE  1 Clinical	characteristics	of	29	cardiac	tamponade	events
Event no Patient no Age (years) Sex BMI (kg/m2) AF type LAD (mm) LV- EF (%) Disease
Anticoagulant 





1 1 63 M 24.7 PAF 37 72 — Warfarin — Left	atrium Done Venous 300
2 2 73 M 21.4 PAF 41 75 — Warfarin — Left	atrium Done Arterial 160
3 3 63 M 23.5 PAF 33 60 — Warfarin — Left	atrium Done Arterial 175
4 4 74 F 20.5 PAF 39 72 — Warfarin — Ward Done Venous 160
5 5 64 M 23.6 PerAF 41 69 — Warfarin Aspirin Left	atrium Done Venous 360
6 6 62 M 25.9 PAF 42 68 — Warfarin — Trans	septum Not	performed — —
7 7 75 F 22.5 PAF 40 68 — Dabigatran — Left	atrium Not	performed — —
8 8 64 M 27.7 PAF 43 72 — Warfarin — Left	atrium Not	performed — —
9 9 68 M 27.6 PAF 34 62 — Warfarin — Left	atrium Done Venous 500
10 10 65 M 21.9 LSPerAF 49 62 — Warfarin — Left	atrium Done Arterial 150
11 10 65 M 21.9 LSPerAF 49 62 — Warfarin — Left	atrium Done Arterial 250
12 11 42 M 28.0 PerAF 36 53 — Warfarin — Ward Done — —
13 12 70 M 22.7 PerAF 42 66 ASD	post	ope Warfarin — Trans	septum Done Arterial 250
14 13 59 M 16.4 PerAF 51 73 — Warfarin — Left	atrium Done Venous 500
15 14 67 M 24.4 PAF 41 64 — Warfarin — Left	atrium Done Arterial 160
16 15 42 M 22.7 PerAF 43 69 — Warfarin — Trans	septum Not	performed — —
17 16 76 M 24.0 PerAF 44 68 AR Warfarin — Ward Done Venous 200
18 17 51 F 28.5 PAF 34 66 — Warfarin — Ward Not	performed — —
19 18 49 F 26.9 PerAF 38 71 Funnel	chest Warfarin — Left	atrium Done Arterial 1000
20 19 65 M 24.5 PerAF 45 63 — Warfarin — After	discharge Done Venous 600
21 20 61 F 30.2 PAF 39 75 — Dabigatran — Left	atrium Done Venous 100
22 21 60 M 21.2 PAF 39 72 HOCM Dabigatran — Left	atrium Done Venous 350
23 22 64 M 26.7 LSPerAF 49 72 — Warfarin — Post	procedure Not	performed — —
24 23 73 F 19.1 PAF 37 60 HOCM Apixaban — Left	atrium Done Venous 250
25 24 80 F 22.0 PAF 39 68 — Not	use — Left	atrium Done Not	
mentioned
1300
26 25 70 M 28.8 PAF 48 70 — Warfarin — Left	atrium Not	performed — —
27 26 66 M 27.3 LSPerAF 42 69 — Rivaroxaban — Left	atrium Done Venous 300
28 27 76 M 23.0 PAF 48 77 VSA Rivaroxaban Clopidogrel Left	atrium Done Venous 1200
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with	rupture	of	an	epicardial	hematoma	or	pericarditis	as	the	pos-
tulated	 causes.	 The	 aim	of	 this	 study	was	 to	 clarify	 the	 clinical	





ycardia	 (AT)	 related	 to	AF	 ablation,	 treated	with	 catheter	 ablation	
between	January	2007	and	January	2016,	were	retrospectively	en-
rolled	 in	 this	 study.	All	 arrhythmias	were	 resistant	 to	 at	 least	 one	
antiarrhythmic	 drug.	Of	 these	 patients,	 29	 events	 (22	males;	 age,	
64.5	±	10.4	year-	old;	 paroxysmal	 AF	 [PAF],	 17;	 Table	1)	 exhib-
ited	 cardiac	 tamponade	 during	 or	 after	 the	 procedure	 (29	 events,	







Event no Patient no Age (years) Sex BMI (kg/m2) AF type LAD (mm) LV- EF (%) Disease
Anticoagulant 





1 1 63 M 24.7 PAF 37 72 — Warfarin — Left	atrium Done Venous 300
2 2 73 M 21.4 PAF 41 75 — Warfarin — Left	atrium Done Arterial 160
3 3 63 M 23.5 PAF 33 60 — Warfarin — Left	atrium Done Arterial 175
4 4 74 F 20.5 PAF 39 72 — Warfarin — Ward Done Venous 160
5 5 64 M 23.6 PerAF 41 69 — Warfarin Aspirin Left	atrium Done Venous 360
6 6 62 M 25.9 PAF 42 68 — Warfarin — Trans	septum Not	performed — —
7 7 75 F 22.5 PAF 40 68 — Dabigatran — Left	atrium Not	performed — —
8 8 64 M 27.7 PAF 43 72 — Warfarin — Left	atrium Not	performed — —
9 9 68 M 27.6 PAF 34 62 — Warfarin — Left	atrium Done Venous 500
10 10 65 M 21.9 LSPerAF 49 62 — Warfarin — Left	atrium Done Arterial 150
11 10 65 M 21.9 LSPerAF 49 62 — Warfarin — Left	atrium Done Arterial 250
12 11 42 M 28.0 PerAF 36 53 — Warfarin — Ward Done — —
13 12 70 M 22.7 PerAF 42 66 ASD	post	ope Warfarin — Trans	septum Done Arterial 250
14 13 59 M 16.4 PerAF 51 73 — Warfarin — Left	atrium Done Venous 500
15 14 67 M 24.4 PAF 41 64 — Warfarin — Left	atrium Done Arterial 160
16 15 42 M 22.7 PerAF 43 69 — Warfarin — Trans	septum Not	performed — —
17 16 76 M 24.0 PerAF 44 68 AR Warfarin — Ward Done Venous 200
18 17 51 F 28.5 PAF 34 66 — Warfarin — Ward Not	performed — —
19 18 49 F 26.9 PerAF 38 71 Funnel	chest Warfarin — Left	atrium Done Arterial 1000
20 19 65 M 24.5 PerAF 45 63 — Warfarin — After	discharge Done Venous 600
21 20 61 F 30.2 PAF 39 75 — Dabigatran — Left	atrium Done Venous 100
22 21 60 M 21.2 PAF 39 72 HOCM Dabigatran — Left	atrium Done Venous 350
23 22 64 M 26.7 LSPerAF 49 72 — Warfarin — Post	procedure Not	performed — —
24 23 73 F 19.1 PAF 37 60 HOCM Apixaban — Left	atrium Done Venous 250
25 24 80 F 22.0 PAF 39 68 — Not	use — Left	atrium Done Not	
mentioned
1300
26 25 70 M 28.8 PAF 48 70 — Warfarin — Left	atrium Not	performed — —
27 26 66 M 27.3 LSPerAF 42 69 — Rivaroxaban — Left	atrium Done Venous 300
28 27 76 M 23.0 PAF 48 77 VSA Rivaroxaban Clopidogrel Left	atrium Done Venous 1200
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in	 detail.	 Ethical	 approval	was	 granted	 by	 the	 institutional	 review	
board	at	Tsukuba	University	Hospital.
2.2 | Ablation procedure and anticoagulation
Antiarrhythmic	 drugs	 were	 discontinued	 for	 at	 least	 five	 half-	
lives	 before	 the	 procedure,	 with	 the	 exception	 of	 amiodarone.	
Atrial	 thrombi	 were	 checked	 by	 transesophageal	 echocardiog-
raphy	on	 the	day	of	 (or	 the	day	before)	 the	procedure.	 Surface	
electrocardiography	 (ECG)	 and	 intracardiac	 electrograms	 were	
continuously	 displayed	 and	 stored	 on	 a	 computer-	based	 digital	
recording	 system	 using	 filter	 settings	 of	 30-	500	Hz	 during	 the	
procedure	(CardioLab	System;	Prucka	Engineering,	Houston,	TX,	
USA).	 In	 conventional	 radiofrequency	 catheter	 ablation	 (RFCA)	
cases,	 through	 a	 single	 transseptal	 puncture,	 a	 3.5	mm	 open-	
irrigated	 deflectable	 catheter	 (ThermoCool;	 Biosense	Webster,	
Diamond	Bar,	CA,	USA)	was	used	for	mapping	and	ablation.	The	
force-	sensing	ablation	catheter	(Smarttouch;	Biosense	Webster)	
was	 used	 if	 it	 was	 possible	 in	 terms	 of	 insurance-	related	 con-
cerns.	Radiofrequency	 (RF)	energy	was	delivered	at	 a	power	of	
20-	35	W,	maximum	 irrigation	 rate	of	30	mL/min,	 and	maximum	
temperature	 of	 42°C.	 The	 ipsilateral	 pulmonary	 vein	 (PV)	 was	
circumferentially	 ablated	 under	 3D	 mapping	 system	 guidance	
(CARTO;	Biosense	Webster;	or	Ensite	Navix;	St	Jude	Medical,	St.	
TABLE  2 Clinical	outcome	of	29	cardiac	tamponade	events




procedure Procedure Contact force
Preventive  
administration Pericarditis Acute recurrence Redo
Midterm  
AF/AT control AF type Drug
1 1 Done 2 6 Yes PVI,	SVC No Yes No No No Yes PAF —
2 2 Done 3 12 No PVI Yes Yes No Yes Yes Yes PAF Propafenone
3 3 Done 2 8 Yes PVI No Yes No No No Yes PAF —
4 4 Done 2 13 Yes PVI,	CTI No Yes No Yes No Yes PAF Propafenone
5 5 Done 2 10 Yes PVI,	roof No Yes No No No Yes PerAF Bepridil
6 6 Not	performed — 7 No C.T.	occurred	before	PVI No Yes No Yes Yes Yes PAF —
7 7 Not	performed — 10 Yes PVI Yes Yes No No No Yes PAF —
8 8 Not	performed — 5 No C.T.	occurred	before	PVI No Yes No Yes Yes Yes PAF —
9 9 Done 3 13 Yes PVI,	CTI No No No No No Yes PAF —
10 10 Done 2 7 No PVI No No No Yes Yes Yes LSPerAF Amiodarone
11 10 Done 3 4 Yes PVI No No No No No Yes LSPerAF Amiodarone
12 11 Done 0 9 No PVI No Yes No Yes Yes Yes PerAF —
13 12 Done 3 11 Yes PVI Yes Yes No Yes No No PerAF Amiodarone
14 13 Done 2 40 No C.T.	occurred	before	PVI No No No Yes Yes No PerAF Amiodarone
15 14 Done 2 12 No C.T.	occurred	before	PVI No No Yes Yes Yes Yes PAF —
16 15 Not	performed — 15 No C.T.	occurred	before	PVI No No Yes Yes Yes Yes PerAF —
17 16 Done 2 14 Yes PVI,	CTI No No Yes Yes No Yes PerAF Amiodarone
18 17 Not	performed — 18 Yes PVI,	SVC,	CTI No No Yes Yes No Yes PAF —
19 18 Done 1 14 Yes PVI Yes No Yes No No Yes PerAF —
20 19 Done 5 10 Yes PVI,	CFAE,	roof,	CTI Yes No Yes No No Yes PerAF —
21 20 Done 2 6 No PVI,	CTI Yes No No Yes Yes Yes PAF —
22 21 Done 3 7 Yes PVI,	CTI Yes Yes No Yes Yes Yes PAF Amiodarone
23 22 Not	performed — 4 Yes PVI,	roof,	CTI Yes No No Yes Yes Yes LSPerAF Amiodarone
24 23 Done 0 7 Yes Cryoballon,	CTI No Yes No No No Yes PAF —
25 24 Done 3 22 Yes PVI Yes Yes Yes Yes No Yes PAF —
26 25 Not	performed — 13 No C.T.	occurred	before	PVI No Yes Yes Yes Yes Yes PAF —
27 26 Done 2 6 Yes PVI,	CTI Yes No Yes No No Yes LSPerAF Amiodarone
28 27 Done 4 19 Yes Cryoballon No No Yes No No Yes PAF —
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Paul,	 MN,	 USA).	 In	 cryoballoon	 cases,	 a	 steerable	 15	F	 sheath	
(Flexcath®;	Medtronic	Inc.,	Minneapolis,	MN,	USA)	was	used	and	
flushed	continuously	with	heparinized	saline.	A	mapping	catheter	
(Achieve®;	Medtronic	 Inc.)	was	 advanced	 into	 each	PV,	 and	PV	
antrum	occlusion	was	considered.	Following	angiography,	a	sin-
gle	3	min	application	was	performed	using	a	second-	generation	
cryoballoon	 (28	mm	 Advance	 balloon;	 Medtronic	 Inc)	 in	 each	
targeted	 PV.	 In	 some	 cases	 of	 PerAF	 and	 LSPerAF,	 a	 left	 atrial	
roof	line,	superior	vena	cave	isolation,	and	complex	fractionated	
atrial	 electrogram	 ablation	were	 added	 at	 the	 discretion	 of	 the	
operator.	If	AT	occurred	after	intravenous	injection	of	isoproter-
enol	and/or	programmed	atrial	stimulation	and	incremental	burst	







In	 the	 case	of	warfarin,	 the	 target	 prothrombin	 time-	international	
normalized	 ratio	 (PT-	INR)	 was	 set	 to	 2.0-	3.0	 in	 patients	 younger	
than	70	years	and	1.6-	2.6	in	those	older	than	70	years.10	All	patients	
underwent	 catheter	 ablation	 without	 interruption	 of	 warfarin	 or	
DOAC.	Immediately	following	the	transseptal	puncture,	5000	units	
TABLE  2 Clinical	outcome	of	29	cardiac	tamponade	events




procedure Procedure Contact force
Preventive  
administration Pericarditis Acute recurrence Redo
Midterm  
AF/AT control AF type Drug
1 1 Done 2 6 Yes PVI,	SVC No Yes No No No Yes PAF —
2 2 Done 3 12 No PVI Yes Yes No Yes Yes Yes PAF Propafenone
3 3 Done 2 8 Yes PVI No Yes No No No Yes PAF —
4 4 Done 2 13 Yes PVI,	CTI No Yes No Yes No Yes PAF Propafenone
5 5 Done 2 10 Yes PVI,	roof No Yes No No No Yes PerAF Bepridil
6 6 Not	performed — 7 No C.T.	occurred	before	PVI No Yes No Yes Yes Yes PAF —
7 7 Not	performed — 10 Yes PVI Yes Yes No No No Yes PAF —
8 8 Not	performed — 5 No C.T.	occurred	before	PVI No Yes No Yes Yes Yes PAF —
9 9 Done 3 13 Yes PVI,	CTI No No No No No Yes PAF —
10 10 Done 2 7 No PVI No No No Yes Yes Yes LSPerAF Amiodarone
11 10 Done 3 4 Yes PVI No No No No No Yes LSPerAF Amiodarone
12 11 Done 0 9 No PVI No Yes No Yes Yes Yes PerAF —
13 12 Done 3 11 Yes PVI Yes Yes No Yes No No PerAF Amiodarone
14 13 Done 2 40 No C.T.	occurred	before	PVI No No No Yes Yes No PerAF Amiodarone
15 14 Done 2 12 No C.T.	occurred	before	PVI No No Yes Yes Yes Yes PAF —
16 15 Not	performed — 15 No C.T.	occurred	before	PVI No No Yes Yes Yes Yes PerAF —
17 16 Done 2 14 Yes PVI,	CTI No No Yes Yes No Yes PerAF Amiodarone
18 17 Not	performed — 18 Yes PVI,	SVC,	CTI No No Yes Yes No Yes PAF —
19 18 Done 1 14 Yes PVI Yes No Yes No No Yes PerAF —
20 19 Done 5 10 Yes PVI,	CFAE,	roof,	CTI Yes No Yes No No Yes PerAF —
21 20 Done 2 6 No PVI,	CTI Yes No No Yes Yes Yes PAF —
22 21 Done 3 7 Yes PVI,	CTI Yes Yes No Yes Yes Yes PAF Amiodarone
23 22 Not	performed — 4 Yes PVI,	roof,	CTI Yes No No Yes Yes Yes LSPerAF Amiodarone
24 23 Done 0 7 Yes Cryoballon,	CTI No Yes No No No Yes PAF —
25 24 Done 3 22 Yes PVI Yes Yes Yes Yes No Yes PAF —
26 25 Not	performed — 13 No C.T.	occurred	before	PVI No Yes Yes Yes Yes Yes PAF —
27 26 Done 2 6 Yes PVI,	CTI Yes No Yes No No Yes LSPerAF Amiodarone
28 27 Done 4 19 Yes Cryoballon No No Yes No No Yes PAF —
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of	 intravenous	heparin	were	given	and	heparinized	 saline	was	 ad-
ministered	via	sustained	injection	to	maintain	the	activated	clotting	
time	 at	 300-	400	s.	 Atrial	 blood	 pressure	 was	monitored	 continu-
ously	from	the	4	Fr	sheath	positioned	within	the	right	femoral	artery.
2.3 | Definition of arrhythmia, cardiac 
tamponade, and pericarditis
Atrial	arrhythmias	were	defined	as	supraventricular	arrhythmias	








at	 onset	 of	 cardiac	 tamponade	 and	 ST	 elevation	 >2	mm	 on	 >6	
leads.
2.4 | Diagnosis and management of 
cardiac tamponade
If	 cardiac	 tamponade	 was	 suspected	 due	 to	 a	 decrease	 in	 blood	
pressure	 or	 unexpected	 catheter	manipulation,	 the	motion	 of	 the	
cardiac	 silhouette	 was	 checked	 in	 the	 left	 anterior	 oblique	 view.	
Pericardial	effusion	was	confirmed	by	transthoracic	or	intracardiac	
echocardiography.	When	 cardiac	 tamponade	was	 confirmed,	 peri-

















2.5 | Definition of acute outcome, midterm 
outcome, AF/AT control, and follow- up
“Acute	 recurrence”	 was	 defined	 as	 AF/AT	 recurrence	 during	 the	
hospital	 stay	 for	 catheter	 ablation.	 “Midterm	 recurrence”	 was	 de-
fined	 as	AF/AT	 recurrence	while	 the	patient	was	being	 followed	 in	
the	outpatient	clinic	or	after	any	 required	 repeat	procedures.	After	










and	 skewed	 variables	 are	 expressed	 as	medians	with	 interquartile	




















27/29 events: S.R. 
(93.1%; 9 with AAD) 
2 events Redo
12 events: S.R. 
(100%; 4 with AAD)











(90.0%; 2 with AAD)
6 events: S.R. 




(94.7%; 7 with AAD)
9/10 events: S.R.
(90.0%; 2 with AAD)








This	 study	 included	 27	 patients	 (29	 events;	 64.5	±	10.4	years;	 22	
men;	body	mass	index,	24.2	±	3.2	kg/m2;	Table	1)	with	cardiac	tam-
ponade	 related	 to	 AF	 ablation.	 The	mean	 left	 atrial	 diameter	was	







3.2 | Causes of cardiac tamponade
Cardiac	tamponade	was	caused	by	intracardiac	catheter	manipula-
tion	 in	 25	 events	 (25/29;	 86.2%),	 atrial	 septum	 puncture	 in	 three	
(3/29;	10.3%),	and	postprocedural	inflammation	in	two	(2/29;	6.9%).	
Regarding	 the	 timing	of	cardiac	 tamponade	occurrence,	23	events	







n = 7 P
Age	(y	±	SD) 64.4	±	9.30 62.7	±	9.44 69.6	±	7.10 0.088
Male,	n 22/28	(78.6%) 18/21	(85.7%) 4/7	(57.1%) 0.111
BMI	(kg/m2) 24.2	±	3.22 24.4	±	3.10 23.8	±	3.76 0.658
PAF,	n 16/28	(57.1%) 10/21	(47.6%) 6/7	(85.7%) 0.078
LAD	(mm) 41.9	±	5.08 41.9	±	5.37 41.9	±	4.45 1.000
LV-	EF	(%) 68.1	±	5.74 67.1	±	5.39 71.1	±	6.10 0.108
Onset	situations
EP	lab,	n 22/28	(78.6%) 16/21	(76.2%) 6/7	(85.7%) 0.595
Ward,	n 4/28	(14.3%) 4/21	(19.0%) 0/7	(0.0%) 0.212
Blood	typeb
Venous	blood,	n 12/19	(63.2%) 7/14	(50.0%) 5/5	(100%) 0.047*
Atrial	blood,	n 7/19	(36.8%) 7/14	(50.0%) 0/5	(0.0%) 0.047*
Pericardiocentesis,	n 22/28	(78.6%) 16/21	(76.2%) 6/7	(85.7%) 0.595








Complete	procedure,	n 18/28	(64.3%) 12/21	(57.1%) 6/7	(85.7%) 0.172
Preventive	 
administration,	n
14/28	(50.0%) 10/21	(47.6%) 4/7	(57.1%) 0.662
Pericarditis,	n 9/28	(32.1%) 7/21	(33.3%) 2/7	(28.6%) 0.815
Acute	recurrence,	n 16/28	(57.1%) 14/21	(66.7%) 2/7	(28.6%) 0.078
Midterm	recurrence,	n 2/28	(7.1%) 2/21	(9.5%) 0/7	(0.0%) 0.397
Pre	CRP	(mg/dL) 0.42	±	1.69 0.09	±	0.12 1.41	±	3.35 0.071
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suite,	four	(4/29;	13.8%)	during	the	ward	stay	after	the	procedure,	
and	two	events	(2/29;	6.9%)	at	10	and	33	days	postprocedure.	In	19	
events	 (19/29,	 65.5%)	 the	 ablation	procedure	was	 completed,	 and	
in	10	(10/29,	34.5%)	it	could	not	be	completed	on	the	first	attempt.	
There	 were	 no	 instances	 of	 cardiac	 tamponade	 associated	 with	
steam	pops.
3.3 | Management of cardiac tamponade
Percutaneous	pericardial	puncture	was	performed	in	21	events	and	
seven	 events	 underwent	 conservative	 treatment	 without	 punc-
ture.	 In	one	event,	 the	puncture	 could	not	be	performed	because	
of	 anatomical	 difficulties	 (Event	 12;	 Table	2).	 The	 average	 volume	
of	initially	drained	blood	was	408	±	345	mL	(21	events;	range,	100-	
1300	mL;	Table	1)	and	the	drain	pigtail	catheter	was	placed	for	an	
average	 of	 2.5	±	1.1	days	 (20	 events;	 range,	 0-	5	days;	 Table	2).	 In	
seven	events	(36.8%;	7/19),	blood	gas	analysis	showed	atrial	blood	
and	12	events	 (63.2%;	12/19)	 showed	venous	blood.	The	hospital	
stay	 was	 11.6	±	7.1	days	 (range,	 4-	40	days).	 No	 patients	 died	 or	
required	 surgical	 repairs	 and	 all	 patients	were	 discharged	 to	 their	
homes.














n = 19 P value
Age	(y	±	SD) 64.5	±	10.4 64.2	±	12.8 65.3	±	7.8 0.771
Male,	n 22/29	(75.9%) 7/10	(70.0%) 15/19	(78.9%) 0.593
BMI	(kg/m2) 24.2	±	3.2 25.2	±	2.5 23.6	±	3.4 0.203
PAF,	n 17/29	(58.6%) 5/10	(50.0%) 12/19	(63.2%) 0.494
LAD	(mm) 41.6	±	5.0 42.2	±	4.4 41.5	±	5.4 0.738
LV-	EF	(%) 68.1	±	5.6 68.5	±	3.9 67.9	±	6.5 0.789
Anticoagulant	drugs
Warfarin	use,	n 21/29	(72.4%) 7/10	(70.0%) 14/19	(73.7%) 0.833
DOAC	use,	n 7/29	(24.1%) 2/10	(20.0%) 5/19	(26.3%) 0.766
Onset	situations
EP	lab,	n 23/29	(79.3%) 7/10	(70.0%) 16/19	(84.2%) 0.369
Ward,	n 4/29	(13.8%) 2/10	(20.0%) 2/19	(10.5%) 0.482
Blood	typea
Venous	blood,	n 12/19	(63.2%) 4/6	(66.7%) 8/13	(61.5%) 0.829
Atrial	blood,	n 7/19	(36.8%) 2/6	(33.3%) 5/13	(38.5%) 0.829
Pericardiocentesis,	n 22/29	(75.9%) 7/10	(70.0%) 15/19	(78.9%) 0.593
Hospital	stay	(days) 11.6	±	7.1 14.3	±	4.6 10.2	±	7.8 0.0048**
Drainage	blood	(mL) 408	±	345	(n	=	21) 680	±	485	(n	=	7) 272	±	124	(n	=	14) 0.071
Complete	procedure,	n 19/29	(65.5%) 7/10	(70.0%) 12/19	(63.2%) 0.713
Preventive	administration,	n 15/29	(51.7%) 2/10	(20.0%) 13/19	(68.4%) 0.013*
Acute	recurrence,	n 17/29	(58.6%) 6/10	(60.0%) 11/19	(57.9%) 0.913
Midterm	recurrence,	n 2/29	(6.9%) 0/10	(0.0%) 2/19	(10.5%) 0.288
Pre	CRP	(mg/dL) 0.41	±	1.7 0.11	±	0.1 0.56	±	2.5 0.498




















warfarin,	 and	 seven	 events	 received	 factor	Xa	 inhibitors	 (apixa-
ban,	 edoxaban,	 rivaroxaban)	 or	 direct	 oral	 thrombin	 inhibitors	
(dabigatran	etexilate).	There	was	no	significant	difference	 in	 the	
clinical	 characteristics	 and	 outcomes	 between	 the	warfarin	 and	
DOAC	groups.	No	significant	differences	in	drained	blood	volume	
(warfarin	 group,	 340	±	240	mL	 vs	 DOAC	 group,	 417	±	393	mL;	
P	=	0.598)	and	hospital	stay	(warfarin	group,	11.7	±	7.53	days,	vs	
DOAC	group,	9.9	±	4.95	days;	P	=	0.560)	were	observed.	Only	the	




3.6 | Pericarditis associated with cardiac tamponade
Among	all	29	events,	10	 (10/29;	34.5%)	developed	pericarditis.	
Most	 cases	 of	 pericarditis	 developed	 immediately	 after	 cardiac	
tamponade;	 however,	 one	 developed	 after	 discharge	 from	 the	
hospital	 (Table	2;	Event	20).	Patients	with	pericarditis	exhibited	
more	 severe	disease	 statuses	 than	 those	without	 (Table	4).	The	
maximum	 C-	reactive	 protein	 values	 were	 higher	 in	 the	 cardiac	
tamponade	with	pericarditis	group	than	in	the	cardiac	tamponade	
without	 pericarditis	 group	 (12.32	±	7.8	 vs	 3.71	±	3.0	mg/dL;	
P	=	0.0002).	 The	 mean	 hospitalization	 was	 also	 longer	 in	 the	
pericarditis	 group	 (14.3	±	4.6	vs	10.2	±	7.8	days;	P	=	0.0048).	 In	
contrast,	there	was	no	statistically	significant	difference	in	mid-
term	outcome	between	 the	 two	 groups	 (with	 pericarditis,	 0/10	
events,	 0.0%;	 without	 pericarditis	 group,	 2/19	 events,	 10.5%;	





vs	 272	±	124	mL;	 P	=	0.071).	 The	 incidence	 rate	 of	 pericarditis	
was	lower	in	the	group	that	received	prophylactic	treatment	than	
in	 the	 group	 that	 did	 not	 (2/15	 events,	 13.3%	 vs	 8/14	 events,	
57.1%;	 P	=	0.013;	 odds	 ratio,	 0.115;	 95%	 confidence	 intervals,	
0.019-	0.717).
3.7 | Delayed tamponade
In	 this	 study,	 only	 two	 events	 developed	 delayed	 tamponade	
(2/2467,	0.081%).	In	one	event,	the	patient	noticed	chest	discom-
fort	 10	days	 after	 catheter	 ablation.	He	 visited	 the	 emergency	
room	after	discharge	and	pericardial	effusion	was	confirmed	via	
echocardiography	 (Figure	2A).	 After	 pericardiocentesis,	 there	




were	 prescribed,	 and	 after	 resolution	 of	 the	 pericarditis,	 the	
patient	 was	 discharged.	 However,	 33	days	 after	 catheter	 abla-
tion,	 he	 experienced	 new-	onset	 dyspnea	 and	 presented	 to	 the	
emergency	 department.	 We	 observed	 increased	 pericardial	
fluid	 and	 inflow	 blockage	 on	 the	 echocardiogram,	 diagnosed	
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pericardiocentesis.	 The	 ST	 elevation	 on	 ECG	 and	 increased	




To	 the	 best	 of	 our	 knowledge,	 this	 study	 describes	 the	 longest	
follow-	up	 period	 for	 patients	 with	 cardiac	 tamponade	 associ-
ated	with	ablation	for	AF.	 In	addition,	only	a	few	reports	have	de-
scribed	 pericarditis	 in	 patients	 with	 cardiac	 tamponade	 and	 the	
relationship	 between	 DOAC	 and	 cardiac	 tamponade.	 Among	 the	
patients	with	cardiac	tamponade	in	our	study,	seven	events	(24.1%)	
were	 prescribed	 DOAC.	 The	 acute	 and	 midterm	 recurrence	 rate	
were	not	significantly	different	 in	 the	DOAC	and	warfarin	groups.	
Pericarditis	occurred	in	10	events	(34.5%)	and	17	(58.6%)	had	an	AF/





4.2 | Acute and midterm outcome in cardiac 
tamponade cases
While	 previous	 studies	 have	 reported	 frequency	 of	 cardiac	 tam-
ponade,	midterm	 outcomes	 are	 lacking.	 In	 this	 study,	 the	 overall	
acute	AF/AT	recurrence	rate	was	58.6%	(17/29).	In	19	events	that	
underwent	 complete	 ablation,	 the	 acute	 AF/AT	 rate	 was	 36.8%	
(7/19).	Conversely,	patients	 in	 the	 incomplete	ablation	group	had	
a	higher	AF/AT	recurrence	rate	(100.0%).	The	results	suggest	that	
complete	ablation	can	help	reduce	the	acute	recurrence	rate.	In	ad-




Latchamsetty et al13 
2011
Bunch et al11 
2005
n = 29 n = 40 n = 15
Incidence of cardiac 
tamponade
29/2467	(1.18%) Not	mentioned 15/617	(2.4%)
Age	(years) 64.5	±	10.4 61.1	±	7.8 54	±	13
Male 22/29	(75.9%) 20/40	(50.0%) 10/15	(66.2%)




Pericarditis 10/29	(34.5%) Not	mentioned 8/15	(53.3%)
Hospital	stay	(days) 11.6	±	7.1 Not	mentioned 6.8	±	4.8
Surgical	operation 0/29	(0.0%) 0/40	(0.0%) 0/15	(0.0%)
Death 0/29	(0.0%) 0/40	(0.0%) 0/15	(0.0%)
Anticoagulant	drug
Warfarin	use 21/29	(72.4%) 40/40	(100.0%) Not	mentioned
DOAC	use 7/29	(24.1%) 0/40	(0.0%) Not	mentioned
Ablation	procedure
RFCA 20/22b	(91.0%) 40/40	(100.0%) 15/15	(100.0%)
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10	 in	 the	 incomplete	group	required	 redo	sessions	after	blanking	
periods	of	3	months	and	most	events	maintained	sinus	rhythm	at	
midterm	follow-	up	(27/29,	93.1%,	with	antiarrhythmic	medication).	
This	 shows	 that	 even	 if	 tamponade	occurs,	 proper	 diagnosis	 and	










4.3 | Causes of cardiac tamponade
A	previous	paper	had	reported	that	steam	pops	can	cause	cardiac	tam-











The	 standard	 procedures	 for	 catheter	 ablation	 are	 changing	 and	
the	number	of	patients	requiring	AF	ablation	continues	to	increase	
worldwide.	 It	 is	 common	 to	 perform	AF	 ablation	while	 continuing	
anticoagulant	 therapy.	As	 long	as	 the	PT-	INR	 is	maintained	within	







4.5 | Pericarditis with cardiac tamponade
A	 case	 of	 pericarditis	 complicated	 with	 cardiac	 tamponade	 was	
previously	 reported	by	Bunch	et	al11	 in	a	study	where	8	of	15	pa-




the	 group	 that	 received	 prophylactic	 treatment	 than	 in	 the	 group	
that	did	not	 (2/15,	13.3%	vs	8/14,	57.1%;	P	=	0.013).	The	cause	of	
pericarditis	 after	 cardiac	 tamponade	 is	 still	 unclear.	The	maximum	
value	of	serum	C-	reactive	protein	was	higher	in	the	pericarditis	group	
(12.32	±	7.8	 vs	 in	 nonpericarditis	 Group,	 3.71	±	3.0,	 P = 0.0002; 
Table	4),	presumably	caused	by	the	pericarditis	itself.	Although	there	







Similarly	 to	 “Dressler	 syndrome”	 and	 “postcardiac	 injury	 syn-




of	 a	 hematoma	 on	 the	 pericardial	 side	 are	 possible	 causes	 of	
this	 rarecomplication.7	 In	 this	 study,	 only	 two	 events	 developed	
delayed	 tamponade	 (2/2467,	 0.081%).	 Both	 patients	 had	 been	
checked	 for	 excess	 pericardial	 fluid	 before	 discharge;	 therefore,	
we	suspect	that	the	pericardial	effusion	increased	during	the	post-
discharge	subacute	phase.	Even	at	several	weeks	after	the	proce-







and	 regular	 follow-	up	 12-	lead	 ECGs,	 24-	h	 Holter	 monitoring,	 or	
event	recordings.	Recurrence	after	ablation	can	be	asymptomatic	
and	we,	 therefore,	may	 have	missed	 some	 cases.	 Third,	we	 used	
the	contact	force	system	in	only	10	events	because	of	insurance-	
related	 concerns.	 The	 use	 of	 a	 contact	 force	 system	may	 affect	
the	occurrence	of	cardiac	tamponade	as	 its	 incidence	may	be	de-








the	occurrence	of	 cardiac	 tamponade,	 or	 a	 repeat	 ablation	proce-
dure	scheduled	later,	the	midterm	outcomes	of	AF	ablation	may	be	
unaffected.
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